<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02428543</url>
  </required_header>
  <id_info>
    <org_study_id>2013-000268-27</org_study_id>
    <nct_id>NCT02428543</nct_id>
  </id_info>
  <brief_title>Ponatinib for FLT3-ITD Acute Myelogenous Leukemia</brief_title>
  <acronym>PONATINIB-AML</acronym>
  <official_title>A Phase I - II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML iIn First Complete Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versailles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versailles Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is part of a joint ALFA and GOELAM strategy aiming to improve the survival of&#xD;
      patients with newly diagnosed Acute Myeloid Leukemia (AML) aged 18-70 years. The basis of&#xD;
      this strategy is to evaluate intensified conventional chemotherapy and targeted drugs in&#xD;
      selected disease-risk subgroups of adult patients with non promyelocytic AML. Participation&#xD;
      will be proposed to almost all adult patients in France aged 18-70 years and diagnosed with&#xD;
      AML.&#xD;
&#xD;
      FLT3 genetic alterations include FLT3 somatic point mutations within the second tyrosine&#xD;
      kinase domain and internal duplications of the juxta-membrane domain. This alteration is&#xD;
      refered to as FLT3-ITD. The FLT3-ITD mutation is found in around 30% of patients with&#xD;
      cytogenetically normal AML. Patients with the FLT3-ITD genotype have been reported to have a&#xD;
      poor outcome when treated with conventional chemotherapy with an estimated 4-year&#xD;
      relapse-free survival of 25% (Schlenk et al. N Engl J Med 2008). More recently, the&#xD;
      prognostic relevance of FLT3-ITD has been studied in the context of integrated genetic&#xD;
      profiling. This confirmed the genetic complexity of AML and also that FLT3-ITD was associated&#xD;
      with reduced overall survival in intermediate-risk AML. A multivariate analysis of several&#xD;
      genetic alterations revealed that FLT3-ITD was the primary predictor of patient outcome.&#xD;
      FLT3-ITD mutations were classified in 3 categories: 1) FLT3-ITD with +8, TET2, DNMT3A or&#xD;
      MLL-PTD mutations (3-year OS 14.5%); 2) FLT3-ITD with wild type CEBPA, TET2, DNMT3 and&#xD;
      MLL-PTD (3-year OS 35.2%) and 3) FLT3-ITD with CEBPA mutations (3-year OS 42%) (Patel JP et&#xD;
      al. N Engl J Med 2012). However, FLT3-ITD was not a predictor of response to induction&#xD;
      therapy, allowing the introduction of targeted therapies after the induction course.&#xD;
&#xD;
      Several FLT3 inhibitors have been evaluated or are currently being tested in the setting of&#xD;
      relapsing AML. In most trials to date, patients were only eligible if the FLT3-ITD mutation&#xD;
      was present. Disappointing results were reported with the first generation of FLT3&#xD;
      inhibitors, including lestaurtinib (CEP-701), midostaurin (PKC-412) and sorafenib. Second&#xD;
      generation FLT3 inhibitors such as quizartinib (AC220) are currently under investigation with&#xD;
      promising results. However, the hematologic toxicity of AC220 will likely present a major&#xD;
      limitation in evaluating AC220 combined with standard or high-dose chemotherapy.&#xD;
&#xD;
      Ponatinib (AP24534) is a third generation tyrosine kinase inhibitor targeting the BCR-ABL&#xD;
      tyrosine kinase domain. Ponatinib was rationally designed with an extensive network of&#xD;
      optimized molecular contacts and triple bonds to accommodate the T315I mutation, a major&#xD;
      cause of resistance to tyrosine kinase inhibitors in chronic and advanced phase chronic&#xD;
      myelogenous leukemia (CML). Ponatinib also inhibits SRC (IC50: 5.4 nM) and members of the&#xD;
      VEGFR, FGFR, and PDGFR families of receptor tyrosine kinases (O'Hare T, Cancer Cell 2009).&#xD;
      Despite low activity against FLT3 based on the IC50 value (FLT3 IC50: 12.6 nM compared to BCR&#xD;
      IC50: 0.37 nM), ponatinib has recently been reported to have significant cellular activity&#xD;
      against the MV4-11 cell line which harbors an FLT3-ITD activating mutation. Ponatinib-induced&#xD;
      apoptosis was maximal at 10 nM in vitro and a single dose of 5 and 10 mg/kg had a strong&#xD;
      inhibitory effect in vivo in mice bearing MV4-11 xenografts. Primary blast cells from 4&#xD;
      FLT3-ITD AML patients were also tested and ponatinib reduced their viability (IC50: 4 nM)&#xD;
      whereas no activity was shown on FLT3-ITD-negative blast cells (Gozgit JM et al. Mol Cancer&#xD;
      Ther 2011).&#xD;
&#xD;
      Preliminary data from the phase I clinical trial showed that 15 mg ponatinib was associated&#xD;
      with a Cmax of 51.1 nM. Cmax was increased to 111 nM and 149 nM in the 30 mg and 45 mg&#xD;
      cohorts respectively. The trough concentrations were 55.3 nM and 61.9 nM for the 30 mg and 45&#xD;
      mg doses respectively (Ariad clinical investigator's brochure, version 3). Results from the&#xD;
      ongoing phase II trial in CML patients suggest that the hematological toxicity profile of&#xD;
      ponatinib is comparable with that of nilotinib or dasatinib, both of which have been&#xD;
      successfully combined with conventional chemotherapy.&#xD;
&#xD;
      Investigators thus aim to combine ponatinib with cytarabine in FLT3-ITD AML patients in first&#xD;
      complete remission.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dose-limiting toxicity (DLT) of ponatinib during consolidation 1 with HDAC or IDAC</measure>
    <time_frame>12 months</time_frame>
    <description>assess the safety of increased doses of ponatinib in combination with high or intermediate -dose cytarabine in AML FLT3-ITD patients in first complete remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>To determine disease-free survival from achievement of first complete remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>To determine overall survival from achievement of first complete remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>To determine overall survival from diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease based on FLT3-ITD quantification, WT1 expression and/or NPM1 mutation quantification</measure>
    <time_frame>18 months</time_frame>
    <description>To study minimal residual disease after induction and consolidation courses based on the quantification of the FLT3-ITD signal and /or WT1, NPM if available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relationship between minimal residual disease and outcome</measure>
    <time_frame>18 months</time_frame>
    <description>To study the relationship between minimal residual disease and outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study ponatinib resistance mechanisms</measure>
    <time_frame>18 months</time_frame>
    <description>To assess FLT3-ITD mutant before and after ponatinib treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Acute Myeloid Lukemia</condition>
  <arm_group>
    <arm_group_label>Ponatinib arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose-escalation Arm _ 15, 30, 45mg Ponatinib per day. Each cohort will consist of 3 evaluable patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib and Cytarabine</intervention_name>
    <description>Prospective, non-randomized, open-label, multicenter, dose-escalation phase I-II trial; an adaptive Bayesian logistic regression dose-escalation model incorporating escalation with overdose control will be used (Babb 1998, Tighiouart 2005). Each cohort will consist of 3 evaluable patients</description>
    <arm_group_label>Ponatinib arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. a. Patients aged 18 to 55-60 years: Cohort A b. Patients aged 55-60 to 70 years:&#xD;
             Cohort B&#xD;
&#xD;
          2. Signed informed consent&#xD;
&#xD;
          3. Acute myeloid leukemia in first complete remission&#xD;
&#xD;
          4. Platelets ≥ 100 Giga/l; Neutrophils ≥ 1 Giga/l&#xD;
&#xD;
          5. Intermediate risk karyotype with FLT3-ITD activating mutant detected at diagnosis&#xD;
             (mutant FLT3/wild-type allelic ratio higher than 10%) (appendix 16)&#xD;
&#xD;
          6. Induction with intensive chemotherapy, dose dense sequential induction or 3 + 7 like&#xD;
             regimen (daunorubicin or idarubicin) for Cohort A and inclusion in the ALFA backbone&#xD;
             for cohort B.&#xD;
&#xD;
          7. Pancreatic functions within the normal range&#xD;
&#xD;
          8. AST or ALT less or equal to 2.5 fold upper normal range, bilirubin less or equal to&#xD;
             1.5 fold upper normal range&#xD;
&#xD;
          9. Serum creatinine less or equal to 1.5 fold upper normal range&#xD;
&#xD;
         10. Two planned consolidation courses with high-dose cytarabine (HDAC, Cohort A) or&#xD;
             intermediate dose cytarabine (IDAC, Cohort B).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute promyelocytic leukemia&#xD;
&#xD;
          2. Transformation of myeloproliferative or myelodysplastic syndromes&#xD;
&#xD;
          3. Known central nervous system involvement&#xD;
&#xD;
          4. Uncontrolled bacterial, viral or fungal infection&#xD;
&#xD;
          5. Other active malignancy&#xD;
&#xD;
          6. Previous episode of pancreatitis&#xD;
&#xD;
          7. Hypertriglyceridemia &gt; 4.5 g/L&#xD;
&#xD;
          8. Lipase &gt; 1.5 × ULN, amylase &gt; 1.5 x ULN not related to leukemia&#xD;
&#xD;
          9. QTc &gt; 470 ms (Bazett formula, see Appendix 1)&#xD;
&#xD;
         10. Patients at high or very high risk of cardiovascular disease with any of the following&#xD;
             f) Established cardiovascular disease&#xD;
&#xD;
               -  Cardiac disease:&#xD;
&#xD;
                    -  Congestive heart failure greater than class II NYHA or&#xD;
&#xD;
                    -  Left ventricular ejection fraction (LVEF) &lt; 50% or&#xD;
&#xD;
                    -  Unstable angina (anginal symptoms at rest) or&#xD;
&#xD;
                    -  New onset angina (began within the last 3 months) or&#xD;
&#xD;
                    -  Myocardial infarction, coronary/peripheral artery disease, congestive heart&#xD;
                       failure, cerebrovascular accident including transient ischemic attack within&#xD;
                       the past 12 months or&#xD;
&#xD;
                    -  History of thrombolic or embolic events&#xD;
&#xD;
               -  Arrhythmias&#xD;
&#xD;
                  - Any history of clinically significant cardiac arrhythmias requiring&#xD;
                  anti-arrhythmic therapy.&#xD;
&#xD;
                  g) Diabetes Mellitus untreated or not equilibrated with therapy h) Arterial&#xD;
                  Hypertension,&#xD;
&#xD;
               -  - Uncontrolled hypertension defined as systolic blood pressure greater than 140&#xD;
                  mmHg or diastolic pressure greater than 90 mmHg, despite optimal medical&#xD;
                  management and optimal measurement&#xD;
                  (http://www.has-sante.fr/portail/display.jsp?id=c_272459)&#xD;
&#xD;
               -  - Any history of hypertension with&#xD;
&#xD;
                    -  Hypertensive encephalopathy&#xD;
&#xD;
                    -  Posterior leucoencephalopathy&#xD;
&#xD;
                    -  Aortic or artery dissection i) Familial dysplipidemia. j) Taking medications&#xD;
                       that are known to be associated with Torsades de Pointes (see Appendix 11)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rousselot Philippe, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Versailles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr Abdelaziz CHAIB</name>
      <address>
        <city>Aix-en-Provence</city>
        <zip>13600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital VICTOR DUPOUY</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Edouard RANDIAMALALA</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Thorsten BRAUN</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Boulogne Sur Mer</name>
      <address>
        <city>Boulogne Sur Mer cedex</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chr Clemenceau</name>
      <address>
        <city>Caen Cedex</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées PERCY</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Stéphanie HAÏAT</name>
      <address>
        <city>Corbeil-essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Versailles</name>
      <address>
        <city>Le Chesnay cedex</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Dupuytren</name>
      <address>
        <city>Limoges cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Regis COSTELLO</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Mario OJEDA-URIBE</name>
      <address>
        <city>Mulhouse</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Jacques DELAUNAY</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice, Hôpital Archet 1</name>
      <address>
        <city>Nice cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris cedex 12</city>
        <zip>75751</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker Enfants Malades</name>
      <address>
        <city>Paris cedex 15</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Laurence SANHES</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Arnaud PIGNEUX</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Dubos</name>
      <address>
        <city>Pontoise Cedex</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marc BERNARD</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Emilie LEMASLE</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Réda GARIDI</name>
      <address>
        <city>Saint-Quentin</city>
        <zip>02100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Christian RECHER</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 2, 2013</study_first_submitted>
  <study_first_submitted_qc>April 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Versailles Hospital</investigator_affiliation>
    <investigator_full_name>Philippe ROUSSELOT</investigator_full_name>
    <investigator_title>Clinical coordinator</investigator_title>
  </responsible_party>
  <keyword>FLT3-ITD patients in first complete remission</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

